CN115927399A - 新抗寨卡病毒疫苗 - Google Patents

新抗寨卡病毒疫苗 Download PDF

Info

Publication number
CN115927399A
CN115927399A CN202211273088.5A CN202211273088A CN115927399A CN 115927399 A CN115927399 A CN 115927399A CN 202211273088 A CN202211273088 A CN 202211273088A CN 115927399 A CN115927399 A CN 115927399A
Authority
CN
China
Prior art keywords
seq
zikv
prme
zika
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211273088.5A
Other languages
English (en)
Chinese (zh)
Inventor
卡鲁皮亚·穆苏马尼
大卫·韦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Original Assignee
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Wistar Institute of Anatomy and Biology filed Critical University of Pennsylvania Penn
Publication of CN115927399A publication Critical patent/CN115927399A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202211273088.5A 2016-02-25 2017-02-24 新抗寨卡病毒疫苗 Pending CN115927399A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201662300030P 2016-02-25 2016-02-25
US62/300,030 2016-02-25
US201662305183P 2016-03-08 2016-03-08
US62/305,183 2016-03-08
US201662396742P 2016-09-19 2016-09-19
US62/396,742 2016-09-19
US201662417100P 2016-11-03 2016-11-03
US62/417,100 2016-11-03
US201762462249P 2017-02-22 2017-02-22
US62/462,249 2017-02-22
PCT/US2017/019407 WO2017147458A1 (en) 2016-02-25 2017-02-24 Novel vaccines against zika virus
CN201780017976.1A CN109152826B (zh) 2016-02-25 2017-02-24 新抗寨卡病毒疫苗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780017976.1A Division CN109152826B (zh) 2016-02-25 2017-02-24 新抗寨卡病毒疫苗

Publications (1)

Publication Number Publication Date
CN115927399A true CN115927399A (zh) 2023-04-07

Family

ID=59685658

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780017976.1A Active CN109152826B (zh) 2016-02-25 2017-02-24 新抗寨卡病毒疫苗
CN202211273088.5A Pending CN115927399A (zh) 2016-02-25 2017-02-24 新抗寨卡病毒疫苗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780017976.1A Active CN109152826B (zh) 2016-02-25 2017-02-24 新抗寨卡病毒疫苗

Country Status (10)

Country Link
US (2) US11648303B2 (enExample)
EP (1) EP3419660A4 (enExample)
JP (3) JP7012365B2 (enExample)
KR (1) KR20190003471A (enExample)
CN (2) CN109152826B (enExample)
AU (3) AU2017222644B2 (enExample)
BR (1) BR112018017307A2 (enExample)
CA (1) CA3015792A1 (enExample)
MX (2) MX2018010291A (enExample)
WO (1) WO2017147458A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US11648303B2 (en) 2016-02-25 2023-05-16 The Trustees Of The University Of Pennsylvania Vaccines against zika virus
CA3040123A1 (en) * 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
CA3081586A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR20200090893A (ko) 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
WO2019113285A2 (en) * 2017-12-06 2019-06-13 Emory University Zika vaccines and methods of use
WO2020019024A1 (en) * 2018-07-23 2020-01-30 The University Of Adelaide Zika virus vaccine
BR112021008217A2 (pt) * 2018-10-31 2021-08-17 Icahn School Of Medicine At Mount Sinai anticorpos humanos que têm como alvo vírus zika ns1, polipeptídeos ns1 e seus usos
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN117120617A (zh) * 2021-02-05 2023-11-24 St制药株式会社 新型核酸分子

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292453A1 (en) * 2005-12-14 2007-12-20 Floyd Robert A RNA virus vaccines and methods
CN102292345A (zh) * 2008-11-17 2011-12-21 Vgx药品有限责任公司 引起对抗黄病毒的免疫应答的抗原及其应用方法
US20160022802A1 (en) * 2013-03-15 2016-01-28 David Weiner Novel Vaccines Against Multiple Subtypes Of Dengue Virus
CN110234346A (zh) * 2016-09-19 2019-09-13 宾夕法尼亚大学理事会 新的对抗寨卡病毒的疫苗和用于对抗寨卡病毒的dna抗体构建体的组合
CN110891600A (zh) * 2017-06-07 2020-03-17 巴斯德研究院 表达寨卡病毒蛋白的重组麻疹病毒及其应用
US20210315987A1 (en) * 2016-02-25 2021-10-14 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014245A1 (en) * 1998-09-02 2000-03-16 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Dengue viruses that are replication defective in mosquitos for use as vaccines
ES2685435T3 (es) * 2008-01-11 2018-10-09 Inovio Pharmaceuticals, Inc. Nuevas vacunas frente a múltiples subtipos del virus del dengue
US8624011B2 (en) * 2009-09-14 2014-01-07 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
JP2013509203A (ja) 2009-11-02 2013-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 口蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列およびそれから生成されるワクチン
US8691961B1 (en) 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
EP2550292B1 (en) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
CN103476928B (zh) * 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
AU2012212264B2 (en) 2011-01-31 2016-01-28 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EP2788478B1 (en) * 2011-12-09 2017-08-23 Institut Pasteur Multiplex immuno screening assay
KR20180036987A (ko) * 2015-07-16 2018-04-10 브하라트 바이오테크 인터내셔날 리미티드 백신 조성물
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MX2018009917A (es) * 2016-02-17 2019-08-14 Curevac Ag Vacuna contra el virus del zika.
EP3484511A4 (en) * 2016-07-18 2020-04-29 Variation Biotechnologies Inc. Vaccine compositions for treatment of zika virus
JP7317715B2 (ja) * 2017-01-11 2023-07-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ジカウイルスに対する免疫応答を誘導するためのヌクレオシド改変ｒｎａ

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292453A1 (en) * 2005-12-14 2007-12-20 Floyd Robert A RNA virus vaccines and methods
CN102292345A (zh) * 2008-11-17 2011-12-21 Vgx药品有限责任公司 引起对抗黄病毒的免疫应答的抗原及其应用方法
US20160022802A1 (en) * 2013-03-15 2016-01-28 David Weiner Novel Vaccines Against Multiple Subtypes Of Dengue Virus
US20210315987A1 (en) * 2016-02-25 2021-10-14 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
CN110234346A (zh) * 2016-09-19 2019-09-13 宾夕法尼亚大学理事会 新的对抗寨卡病毒的疫苗和用于对抗寨卡病毒的dna抗体构建体的组合
CN118652897A (zh) * 2016-09-19 2024-09-17 宾夕法尼亚大学理事会 新的对抗寨卡病毒的疫苗和用于对抗寨卡病毒的dna抗体构建体的组合
CN110891600A (zh) * 2017-06-07 2020-03-17 巴斯德研究院 表达寨卡病毒蛋白的重组麻疹病毒及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VAZQUEZ-PICHARDO, M.等: "Zika virus isolate MEX/InDRE/14/2015 polyprotein gene, partial cds", GENBANK DATABASE, 18 February 2016 (2016-02-18), pages 686218 *
詹瑛;邓瑶;谭文杰;: "寨卡病毒新型疫苗的研究进展", 病毒学报, no. 06, 31 December 2017 (2017-12-31), pages 128 - 133 *

Also Published As

Publication number Publication date
AU2021258056B2 (en) 2024-04-04
AU2017222644B2 (en) 2021-07-29
CN109152826B (zh) 2022-11-04
EP3419660A4 (en) 2019-11-06
WO2017147458A1 (en) 2017-08-31
US11648303B2 (en) 2023-05-16
US20240115689A1 (en) 2024-04-11
KR20190003471A (ko) 2019-01-09
JP2024096281A (ja) 2024-07-12
AU2021258056A1 (en) 2021-11-25
US12419945B2 (en) 2025-09-23
US20210315987A1 (en) 2021-10-14
MX2023006203A (es) 2023-06-12
BR112018017307A2 (pt) 2019-01-08
EP3419660A1 (en) 2019-01-02
JP7012365B2 (ja) 2022-03-04
JP2022023241A (ja) 2022-02-07
AU2017222644A1 (en) 2018-09-13
MX2018010291A (es) 2019-06-06
JP7555325B2 (ja) 2024-09-24
AU2024204641A1 (en) 2024-07-25
CN109152826A (zh) 2019-01-04
CA3015792A1 (en) 2017-08-31
JP2019506175A (ja) 2019-03-07

Similar Documents

Publication Publication Date Title
US12419945B2 (en) Vaccines against Zika virus
JP5744719B2 (ja) チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
US20190091322A1 (en) Dna antibody constructs and method of using same
US20240226291A9 (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
KR20160091350A (ko) 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
HK40091502A (zh) 新抗寨卡病毒疫苗
Liao et al. Co‐delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced Th1‐dominant humoral and cellular immunity against SARS‐CoV‐2
EP4333887A1 (en) Vaccines against coronavirus and methods of use
US20240016919A1 (en) INTRADERMAL MERS-CoV VACCINE
CN117479953A (zh) 针对冠状病毒的疫苗及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091502

Country of ref document: HK